C4 Therapeutics, Inc.
C4 Therapeutics, Inc. is listed today as C4 Therapeutics, Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Dec 2015 | $70 M | No. 1 | $50 to $250 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
C4 Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2016).
SEC Form D · Jan 2016
The industry group it chose in its notices: Biotechnology.
SEC Form D · Jan 2016
That is all the official record says: C4 Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of C4 Therapeutics, Inc. are on record.
Investors#
3 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Bruce Downey | Person | not stated | not stated | Held Series A and B preferred stock, director (Form 3, 2020) | SEC Form 3 |
| Kenneth Carl Anderson | Person | not stated | not stated | Held Series A preferred stock, director (Form 3, 2020) | SEC Form 3 |
| Malcolm Salter | Person | not stated | not stated | Held Series A and B preferred stock, director (Form 3, 2020) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 55 investors.
Largest shareholders today
Institutions holding C4 Therapeutics, Inc. shares, as of Sep 30, 2026.
- Squadron Capital Management LLC$31 M7.10%
- Morgan Stanley$30 M6.76%
- Ra Capital Management, L.P.$27 M6.24%
- BlackRock, Inc.$27 M6.23%
- Lynx1 Capital Management LP$25 M5.73%
- Bain Capital Life Sciences Investors, LLC$24 M5.46%
- Citadel Advisors LLC$17 M3.81%
- Jpmorgan Chase & Co$16 M3.58%
- Goldman Sachs Group Inc$16 M3.57%
- Vanguard Capital Management LLC$15 M3.49%
- Wasatch Advisors LP$14 M3.17%
- Boxer Capital Management, LLC$14 M3.16%
- Two Sigma Investments, LP$12 M2.85%
- Silverarc Capital Management, LLC$12 M2.63%
- Soleus Capital Management, L.P.$11 M2.56%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Jason Fisherman | Executive officer | Jan 2016 |
| Marc Cohen | Executive officer | Jan 2016 |
| Alain Cohen | Director | Jan 2016 |
| Bihua M. Chen | Director | Jan 2016 |
| Bruce M. Downey | Director | Jan 2016 |
| Elena M. Prokupets | Director | Jan 2016 |
| Jason Fisherman | Director | Jan 2016 |
| Jay M. Eastman | Director | Jan 2016 |
| Kenneth M. Anderson | Director | Jan 2016 |
| Malcolm S. Salter | Director | Jan 2016 |
| Marc Cohen | Director | Jan 2016 |
| Miles M. Stuchin | Director | Jan 2016 |
| Ronald W. Kaiser | Director | Jan 2016 |
| William M. Scalzulli | Director | Jan 2016 |
About
Company in Watertown, United States.
Went public since 2020. Its SEC number is that of a company listed on a stock exchange.